0000000000294051

AUTHOR

Felice Piccinino

showing 4 related works from this author

Decrease in HDV endemicity in Italy.

1997

To evaluate a possible variation in hepatitis D virus endemicity in Italy, the data from a multicentre study concerning HBsAg chronic carriers first observed in 31 liver units during 1992 were compared with the corresponding figures from a similar study performed in 1987.In both studies the methodology for the recruitment of cases was the same. The overall anti-HD prevalence in 1992 was 14.4%, a significantly lower rate than that observed in 1987 (23.4%, p0.01). The decrease significantly (p0.01) affected both males and females; it occurred in all geographical areas, although to a greater extent in northern regions. It was evident in subjects below 50 years of age, but not in subjects older…

AdultMaleHBsAgmedicine.medical_specialtyCirrhosisAdolescentEndemic DiseasesVirusRisk FactorsEpidemiologymedicinePrevalenceHumansChildHepatitis B Surface AntigensHepatologyHepatitis D virus infectionbusiness.industryClinical Laboratory TechniquesIncidence (epidemiology)Infant NewbornInfantMiddle Agedmedicine.diseaseVirologyHepatitis DItalyChild PreschoolCarrier StateFemaleViral diseaseHepatitis D virusbusinessJournal of hepatology
researchProduct

Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop

2011

Abstract The Italian recommendations for the therapy of hepatitis B virus (HBV)-related disease were issued in 2008. Subsequently in 2008 the nucleotide analogue (NA) Tenofovir was approved for antiviral treatment. The introduction of this important new drug has called for the current guidelines update, which includes some additional revisions: (a) the indication for therapy is extended to mild liver fibrosis and the indication for treatment is graded as “possible”, “optional” or “mandatory” according to the fibrosis stage; (b) two different treatment strategies are described: first line definite duration treatment with interferon, long-term treatment of indefinite duration with NA; (c) the…

Liver Cirrhosismedicine.medical_specialtyHepatitis B virusCirrhosisCarcinoma HepatocellularOrganophosphonateschronic hepatitis B The Italian recommendations for the therapy of hepatitis B Tenofovir Adefovir Cirrhosis Telbivudine Lamivudine Entecavirmedicine.disease_causeAntiviral Agentsadefovir; cirrhosis; entecavir; hbv; lamivudine; telbivudine; tenofovirHepatitis B ChronicInternal medicineTelbivudinemedicineAdefovirHBVHumansStage (cooking)TenofovirHepatitis B virusHepatologybusiness.industryAdenineLiver NeoplasmsGastroenterologyLamivudineEntecavirmedicine.diseaseVirologyItalyHepatocellular carcinomaReverse Transcriptase InhibitorsInterferonsbusinessmedicine.drug
researchProduct

Real-world outcomes in patients with chronic hepatitis C: primary results of the PROBE study.

2014

BACKGROUND This large prospective multicentre cohort study aimed to improve knowledge of therapy for chronic hepatitis C (CHC) in real clinical practice. METHODS A diverse population of adults with CHC including patients with comorbid conditions, laboratory abnormalities and demographic features [comorbidities or special populations (CSP)] who were under-represented or excluded from peginterferon registration studies was treated with peginterferon α-2a (40 kDa) or α-2b (12 kDa) plus ribavirin at the investigator's discretion. RESULTS During the study, 5399 treatment-naive patients [2527 (46.8%) with CSP] received peginterferon α-2a (n=3513, 65.1%) or peginterferon α-2b (n=1886, 34.9%). The …

MaleCirrhosisTime FactorsComorbidityHepacivirusmedicine.disease_causePolyethylene Glycolschemistry.chemical_compoundRecurrencepeginterferonProspective Studiesspecial populationAged 80 and overbiologyRemission InductionGastroenterologyvirus diseasesMiddle AgedViral LoadRecombinant ProteinsTreatment OutcomeItalyHCVRNA ViralDrug Therapy CombinationFemalesustained virological responseCohort studyAdultcomorbiditiemedicine.medical_specialtyAdolescentGenotypeHepatitis C virusInterferon alpha-2Antiviral AgentsYoung AdultChronic hepatitisInternal medicineRibavirinmedicineHumansIn patientMedical prescriptionAgedHepatologybusiness.industryRibavirinInterferon-alphaHepatitis C Chronicmedicine.diseasechemistryAlanine transaminaseImmunologybiology.proteinbusinessEuropean journal of gastroenterologyhepatology
researchProduct

Familiar clustering and spreading of hepatitis delta virus infection

1985

The prevalence of hepatitis delta virus (HDV) infection was significantly higher among the relatives of 79 carriers of HBsAg with antibody to HDV (index cases) than among relatives of 111 carriers without serological evidence of HDV infection (controls). Antibody to HDV was found in 45 of the 80 (56%) carriers of HBsAg in families of index cases but only in 2 of 59 (3%) carriers in families of controls (P less than 0.0001). During follow-up new HDV infection developed in 31% of 13 susceptible carriers in families of index cases, but only in 1.2% of 162 susceptible carriers in families of controls (P less than 0.001). None of the family members previously unexposed to the hepatitis B virus h…

AdultMaleHBsAgvirusesmedicine.disease_causeVirusmedicineHumansHepatitis B virusHepatologybiologyInfantvirus diseasesbiochemical phenomena metabolism and nutritionHepatitis BHepatitis Bmedicine.diseaseHepatitis DVirologyHepatitis DChild PreschoolCarrier StateImmunologybiology.proteinFemaleViral diseaseAntibodyViral hepatitisFollow-Up Studies
researchProduct